NasdaqCM · Biotechnology

Minerva Neurosciences (NERV)

Stock, pipeline and biotech catalyst intelligence

Analyst view

Buy+113.5%

$10.33 average target

$4.84+0.05 (+1.0%)Latest market snapshot · Yahoo Finance

Market cap$231.1M

Cash$75.3M

Quarterly burn$13.3M

Pipeline assets2

Short float5.4%

Latest coverage

News & Press Releases

External sources

Aug 7, 2026

Minerva Neurosciences Provides Second Quarter 2026 Financial Results and Business UpdatesGlobeNewswire

Aug 7, 2026

Minerva Neurosciences: Q2 Earnings SnapshotAssociated Press

Jun 1, 2026

Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline ProgramsGlobeNewswire

Company profile

About Minerva Neurosciences

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.

Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.